Drug Profile

Research programme: fimaporfin delivered nucleic acid therapeutics - PCI Biotech

Alternative Names: fimaNAc

Latest Information Update: 12 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PCI Biotech
Class MicroRNAs; RNA; Small interfering RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Skin disorders

Most Recent Events

07 Sep 2023 PCI Biotech has patent pending for mRNA delivery with fimaNAc in Europe, USA and other Asian countries
17 Feb 2023 PCI Biotech files for patent protection for the use of fimaNAc in viral vector manufacturing
05 Jan 2022 PCI Biotech enters a preclinical research collaboration with MDimune for development of fimaVacc

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com